This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • World Health  • HIV/AIDS  • Alert me on articles by topic

Substantial Benefit But Limited Access

Joseph I. Harwell, MD; Stephen K. Obaro, MD, FRCPCH, PhD

JAMA. 2006;296:330-331.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

According to the United Nations Programme on HIV/AIDS (UNAIDS) global report on human immunodeficiency virus (HIV), in 2005 more than 2.3 million children were living with HIV infection, and 380 000 children with HIV had died.¹ Most of the children who die from HIV have severe manifestations of common childhood illnesses, such as diarrhea, malnutrition, acute respiratory tract infection, and tuberculosis.^2-4 These children often die before the diagnosis of HIV infection can be made, and mortality is often attributed to a background high rate of early childhood mortality.

The United States is home for a diminishing proportion of HIV-infected children, with an estimated 11 000 cases in 2005.¹ There are 2 reasons for this decreasing population of HIV-infected children in the developed world. First, pregnant women are increasingly being offered HIV testing, and HIV-infected women are receiving antiretroviral medications sufficient to reduce . . . [Full Text of this Article]

Author Affiliations: Division of Infectious Diseases, Departments Medicine and Pediatrics, Brown Medical School, Rhode Island and Miriam Hospitals, Providence (Dr Harwell) and Department of Pediatrics, Children's Hospital of Pittsburgh, Pittsburgh, Pa (Dr Obaro).

RELATED ARTICLE

Incidence of Opportunistic and Other Infections in HIV-Infected Children in the HAART Era
Philimon Gona, Russell B. Van Dyke, Paige L. Williams, Wayne M. Dankner, Miriam C. Chernoff, Sharon A. Nachman, and George R. Seage, III
JAMA. 2006;296(3):292-300.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children
Larru et al.
J Antimicrob Chemother 2008;61:183-190.
ABSTRACT | FULL TEXT